Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study(vol 17, 218, 2022)
Jiang Li,Zhu Jie,Chen Xue,et al.Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study(vol 17, 218, 2022)[J].RADIATION ONCOLOGY.2023,18(1):doi:10.1186/s13014-023-02245-0.
APA:
Jiang, Li,Zhu, Jie,Chen, Xue,Wang, Yi,Wu, Lei...&Wang, Qifeng.(2023).Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study(vol 17, 218, 2022).RADIATION ONCOLOGY,18,(1)
MLA:
Jiang, Li,et al."Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study(vol 17, 218, 2022)".RADIATION ONCOLOGY 18..1(2023)